08:00 , Nov 25, 2002 |  BC Week In Review  |  Company News

KS Biomedix management update

KS Biomedix Holdings plc (LSE:KSB), Guildford, U.K.   Business: Autoimmune/Inflammation, Cancer   Hired: David Cox as CEO of KSB's manufacturing subsidiary KS Avicenna Inc., formerly CEO of Synsorb Biotech Inc.  ...
07:00 , Sep 23, 2002 |  BioCentury  |  Finance

Ebb & Flow

Investors voted with their feet after learning that they will have to wait even longer for regulatory clarity over competing compounds for Fabry disease from Genzyme (GENZ) and Transkaryotic (TKTX). On Friday, the FDA postponed...
07:00 , Sep 17, 2002 |  BC Extra  |  Company News

KSB licenses TransMID to Nycomed

KS Biomedix (LSE:KSB) granted Nycomed Group (Roskilde, Denmark) European rights to its TransMID therapeutic for brain cancer. TransMID has completed a U.S. Phase II trials to treat recurrent brain cancer. The companies will jointly fund...
07:00 , Jun 3, 2002 |  BC Week In Review  |  Company News

KS Biomedix Holding plc, Sosei Co. Ltd. deal

KSB granted Sosei Japanese rights to its Phase II TransMID product to treat recurrent high grade glioma. KSB will manufacture and sell TransMID materials to Sosei, which will be responsible for development, registration and marketing...
07:00 , May 28, 2002 |  BC Extra  |  Company News

KSB, Sosei TransMID deal

KS Biomedix (LSE:KSB) granted Sosei (Tokyo, Japan) Japanese rights to its Phase II TransMID treatment for recurrent high grade glioma. KSB will manufacture and sell TransMID materials for Sosei , which will be responsible for...
07:00 , Aug 6, 2001 |  BC Week In Review  |  Clinical News

TransMID-107R transferrin-mediated delivery of diphtheria toxin regulatory update

The FDA granted Fast Track status to KSB's TansMID-107R to treat recurrent, inoperable high-grade gliomas in adults. The product, which is expected to enter Phase III trials in 2002, was developed by Avicenna Medica (see...
07:00 , Jul 13, 2001 |  BC Extra  |  Financial News

KS Biomedix raises $26.7 million

KS Biomedix (LSE:KSB) completed its previously announced placing and open offer for 6 million shares at 315p, raising L19 million ($26.7 million). Of the total, 5.5 million shares went to institutional investors, with 571,623 going...
07:00 , Jul 2, 2001 |  BioCentury  |  Strategy

KSB's antibody strategy

KS Biomedix Holdings plc believes that its technology for generating high-affinity sheep antibodies has benefits over competing antibody technologies. But the company's lack of a target identification capability has left its cupboard of actual antibody...
07:00 , Jun 25, 2001 |  BC Week In Review  |  Company News

Avicenna Inc., Intracel Corp., KS Biomedix deal

KSB will acquire cancer and contract manufacturing play Avicenna for £41.9 million ($59 million) comprising £37.2 million in stock valued at £4.30 per share and £4.65 million in cash. Avicenna has two technologies for delivery...
07:00 , Jun 25, 2001 |  BioCentury  |  Finance

Ebb & Flow

The $66.6 million raised by four European companies last week may have looked paltry compared to the $895 million raised in the U.S. But the week's biggest deal, the £25 million ($35.1 million) IPO in...